Junshi
Junshi Biosciences Announces Phase 3 Win for IL-17A Drug JS005 in Psoriasis, Prepares China NDA Submission
Junshi Biosciences; JS005; IL-17A monoclonal antibody; psoriasis; phase 3 trial; clinical endpoints; China drug approval
Leo Pharma Acquires EU Rights to Loqtorzi, Boosting Marketing Efforts for PD-1 Inhibitor
Loqtorzi, PD-1 Inhibitor, Nasopharyngeal Carcinoma, EU Rights, Leo Pharma, Junshi Biosciences, Marketing Efforts